Ventrus Biosciences, Inc. Validates Large Patient Potential for VEN 309 With Survey Data From 10,000 Consumers

NEW YORK, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today an update to the timing for the reporting of the top line results from the ongoing Phase 3 pivotal trial of Iferanserin (VEN 309) in patients with hemorrhoids as well as from the ongoing Phase 3 pivotal trial of Diltiazem (VEN 307) in patients with anal fissures. The company has extended the timing to report the top line results from the hemorrhoid trial by approximately three months, to around June 2012 while top line data for the anal fissure trial is still expected around May 2012.